Significantly higher levels of anti-HIV antibodies induced by EboGP-pseudotyped HIV VLPs compared with native HIV VLPs in C57BL/6 mice.

A) Schematic of the HIV Env or EboGP-pseudotyped HIV VLP immunization protocol used in this study. The C57BL/6 mice were injected subcutaneously with 100 ng of HIVgp-VLPs, or EboGP/HIVgp-VLPs, as indicated. At 21 and 49 days post-immunization, mice were boosted with same amounts of VLPs, and sera and spleens were collected at 56 days of post-immunization. B) Mice body weights were monitored weekly in which 100% body weight was set at day 0. The levels of anti-EboGP (C), anti-HIVgp120 (D), anti-HIVp24 (E) antibodies in the sera of immunized C57BL/6 mice were detected by corresponding ELISAs. The value is the individual amount for each mouse of each group. Statistical significance was determined using unpaired t—test, and significant p values are represented with asterisks, *≤0.05, **≤0.01, ***≤0.001.